Sanofi Nears Deal to Buy Hemophilia Drugmaker Bioverativ for More Than $11.5 Billion
January 21 2018 - 08:49PM
Dow Jones News
By Dana Mattioli and Jonathan D. Rockoff
Sanofi SA is nearing a deal to buy hemophilia drugmaker
Bioverativ Inc. for more than $11.5 billion as the French drugmaker
looks set to clinch a big deal while it braces for generic
competition for its top-selling product.
A deal, which could be announced as soon as Monday, would value
the former Biogen Inc. unit at $105 a share, according to people
familiar with the matter. The price would represent a 63% premium
to where Bioverativ closed trading Friday. It is possible the talks
could fall apart before a deal is reached.
(More to come)
(END) Dow Jones Newswires
January 21, 2018 20:34 ET (01:34 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Bioverativ Inc. (NASDAQ:BIVV)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bioverativ Inc. (NASDAQ:BIVV)
Historical Stock Chart
From Mar 2023 to Mar 2024